These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 17352522)

  • 1. Clopidogrel: a review of its use in the prevention of thrombosis.
    Plosker GL; Lyseng-Williamson KA
    Drugs; 2007; 67(4):613-46. PubMed ID: 17352522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial.
    Wiviott SD; Braunwald E; McCabe CH; Horvath I; Keltai M; Herrman JP; Van de Werf F; Downey WE; Scirica BM; Murphy SA; Antman EM;
    Lancet; 2008 Apr; 371(9621):1353-63. PubMed ID: 18377975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clopidogrel: a review of its use in the prevention of atherothrombosis.
    Jarvis B; Simpson K
    Drugs; 2000 Aug; 60(2):347-77. PubMed ID: 10983738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clopidogrel: a pharmacoeconomic review of its use in patients with non-ST elevation acute coronary syndromes.
    Lyseng-Williamson KA; Plosker GL
    Pharmacoeconomics; 2006; 24(7):709-26. PubMed ID: 16802846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance.
    Depta JP; Bhatt DL
    Am J Cardiovasc Drugs; 2008; 8(2):91-112. PubMed ID: 18422393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clopidogrel: potential in the prevention of cardiovascular events in patients with acute coronary syndromes.
    Easthope SE; Jarvis B
    Am J Cardiovasc Drugs; 2001; 1(6):467-74; discussion 475-6. PubMed ID: 14728005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clopidogrel: the future choice for preventing platelet activation during coronary stenting?
    Gurbel PA; O'Connor CM; Cummings CC; Serebruany VL
    Pharmacol Res; 1999 Aug; 40(2):107-11. PubMed ID: 10433868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacy clinics. Medication of the month. Clopidogrel (Plavix)].
    Scheen AJ
    Rev Med Liege; 2001 Mar; 56(3):186-9. PubMed ID: 11338792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence with antiplatelet therapy and ADP-receptor antagonists.
    Easton JD
    Cerebrovasc Dis; 2003; 16 Suppl 1():20-6. PubMed ID: 12698015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement.
    Müller I; Besta F; Schulz C; Massberg S; Schönig A; Gawaz M
    Thromb Haemost; 2003 May; 89(5):783-7. PubMed ID: 12719773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiplatelet drug resistance and variability in response: the role of antiplatelet therapy monitoring.
    Tantry US; Gurbel PA
    Curr Pharm Des; 2013; 19(21):3795-815. PubMed ID: 23286432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variability of platelet response to clopidogrel is not related to adverse cardiovascular events in patients with stable coronary artery disease undergoing percutaneous coronary intervention.
    Olędzki S; Kornacewicz-Jach Z; Safranow K; Kiedrowicz R; Gawrońska-Szklarz B; Jastrzębska M; Gorący J
    Eur J Clin Pharmacol; 2017 Sep; 73(9):1085-1094. PubMed ID: 28589365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prasugrel (Effient) vs. clopidogrel (Plavix).
    Med Lett Drugs Ther; 2009 Sep; 51(1320):69-70. PubMed ID: 19738549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Dasbiswas A; Rao MS; Babu PR; Vijayvergiya R; Nayak R; Dani S; Tyagi S; Hiremath S; Patel T; Alexander T; Prakash VS; Singh DP; Yadav MK; Pathak K; Srivastava A
    J Assoc Physicians India; 2013 Feb; 61(2):114-6, 126. PubMed ID: 24471250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clopidogrel.
    Coukell AJ; Markham A
    Drugs; 1997 Nov; 54(5):745-50; discussion 751. PubMed ID: 9360060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
    Mehta SR; Tanguay JF; Eikelboom JW; Jolly SS; Joyner CD; Granger CB; Faxon DP; Rupprecht HJ; Budaj A; Avezum A; Widimsky P; Steg PG; Bassand JP; Montalescot G; Macaya C; Di Pasquale G; Niemela K; Ajani AE; White HD; Chrolavicius S; Gao P; Fox KA; Yusuf S;
    Lancet; 2010 Oct; 376(9748):1233-43. PubMed ID: 20817281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
    Parodi G; Marcucci R; Valenti R; Gori AM; Migliorini A; Giusti B; Buonamici P; Gensini GF; Abbate R; Antoniucci D
    JAMA; 2011 Sep; 306(11):1215-23. PubMed ID: 21934054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
    Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E;
    Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
    Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
    JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
    Motovska Z; Kala P
    Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.